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ABSTRACT 27 
Lead (Pb2+) exposure during brain development inhibits neurotransmitter release 28 
resulting in impaired synapse formation, synaptic plasticity and learning. In primary 29 
hippocampal neurons in culture and hippocampal slices, Pb2+ exposure inhibits vesicular 30 
release and reduces the number of fast-releasing sites, an effect associated with Pb2+ 31 
inhibition of NMDA receptor-mediated trans-synaptic BDNF signaling. We hypothesized 32 
that TrkB receptor activation, the cognate receptor for BDNF, would rescue Pb2+-induced 33 
impairments of vesicular release. Rats were chronically exposed to Pb2+ prenatally and 34 
postnatally until 50 days of age. This Pb2+ exposure paradigm enhanced paired-pulse 35 
facilitation representative of reduced vesicular release probability. Reductions in Pb2+-36 
induced release probability were also measured by both mean-variance analysis and 37 
direct two-photon imaging of vesicular release from hippocampal slices. We also found a 38 
Pb2+ impairment of calcium influx in presynaptic terminals. Intraperitoneal injections of 39 
the TrkB agonist 7,8-dihydroxyflavone (5 mg/kg) for 14-15 days in Pb2+ rats starting at 40 
postnatal day 35, reversed all Pb2+-induced impairments of presynaptic transmitter 41 
release at Schaffer collateral-CA1 synapses. These data indicate that in vivo 42 
pharmacological activation of TrkB receptors can reverse long-term effects of chronic 43 
Pb2+ exposure on presynaptic terminals, pointing to TrkB receptor activation by small 44 
molecules as a promising therapeutic intervention in Pb2+-intoxicated children.  45 
 46 
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Childhood lead (Pb2+) intoxication is a significant public health problem in the United 52 
States and globally1,2. Recent episodes of Pb2+ exposure in children in communities like 53 
Flint, Michigan demonstrate the pervasive nature of the problem3. The National 54 
Resources Defense Council (NRDC) reports that millions of Americans get drinking 55 
water from water systems that have Pb2+ violations and the problem could be much 56 
larger, because systems known to have violations do not show up in government 57 
databases that track such problems. Despite nearly a century of knowledge on the 58 
detrimental effects of Pb2+ in children’s development, the widespread presence of this 59 
poison in the global environment continues to affect children in the most vulnerable and 60 
economically disadvantaged segments of the population.  61 
 62 
Studies have consistently demonstrated that one of the most prominent effects of Pb2+ in 63 
children is decreased capacity to learn, with devastating effects on cognitive and 64 
intellectual development4-8, and in-school performance9,10. Early life Pb2+ intoxication 65 
diminishes intellectual capacity of children with an immeasurable cost to society. Human 66 
studies have shown that Pb2+ exposure in early life is associated with longitudinal 67 
declines in cognitive function11, loss of brain volume12,13, and emergence of mental 68 
disorders such as major depression and schizophrenia14,15. 69 
 70 
Our laboratory has provided the first working model by which Pb2+ exposure during the 71 
period of synaptogenesis can affect synapse development and function, that accounts 72 
for both presynaptic and postsynaptic effects of Pb2+ on the synapse16-18. Using a Pb2+ 73 
exposure paradigm during the period of synaptogenesis in primary hippocampal 74 
neurons, we found that Pb2+ inhibition of postsynaptic NMDA receptors (NMDAR) 75 
impairs CREB-dependent transcription of activity-regulated genes such as brain-derived 76 
neurotrophic factor (BDNF), and alters the function of its cognate receptor TrkB and 77 
 4
downstream signaling and alters vesicle movement16-18. These studies also showed that 78 
Pb2+-induced impairment of BDNF trans-synaptic retrograde signaling decreases the 79 
presynaptic vesicular proteins synaptophysin and synaptobrevin and inhibits vesicular 80 
release16. The addition of exogenous BDNF to Pb2+-exposed hippocampal neurons 81 
normalized synaptophysin and synaptobrevin levels and reversed the impairment in 82 
vesicular release, providing the first evidence of the beneficial effects of BDNF on Pb2+-83 
induced synaptic dysfunction16. Consistent with these observations, electrophysiological 84 
and two-photon imaging studies at Schaffer collateral-CA1 synapses in ex vivo 85 
hippocampal slices from rats chronically exposed to Pb2+ during development, revealed 86 
a marked inhibition of hippocampal Schaffer-collateral-CA1 synaptic transmission by 87 
inhibiting vesicular release19.  88 
 89 
In the present study, we determined whether BDNF activation of its cognate receptor, 90 
TrkB, could rescue the Pb2+-induced deficits in vesicular release observed in Pb2+ 91 
exposed animals in vivo. We used 7,8-dihydroxyflavone (7,8-DHF), a small, CNS 92 
permeant molecule from the flavonoid family that is a BDNF mimetic and activates TrkB 93 
receptors20. 7,8-DHF exhibits promising therapeutic efficacy in animal models of 94 
neurodegenerative diseases20-22. Based on our previous in vitro studies demonstrating a 95 
beneficial effect of BDNF on Pb2+-induced inhibition of vesicular release, we 96 
hypothesized that 7,8-DHF could be useful to assess in our in vivo Pb2+ exposure 97 
paradigm. Here we demonstrate that 7,8-DHF can rescue the inhibition of hippocampal 98 
Schaffer-collateral-CA1 vesicular release resulting from developmental Pb2+ exposure. 99 
 100 
 101 
 102 
 103 
 5
RESULTS 104 
Blood Pb2+ levels and body weight of rats: 105 
The Pb2+ exposure paradigm did not produce any overt toxicity based on body weight 106 
gain. Body weights at postnatal day 50 (PN50) rats were: 264.4 ± 11.9 g (n=10) for 107 
control animals plus or minus 7,8-DHF and 231.9 ± 10.0 g (n=14) for Pb2+-exposed 108 
animals plus or minus 7,8-DHF (p>0.05). Further, blood Pb2+ levels of littermates to 109 
animals used in this study at PN50 were: 0.6 ± 0.1 μg/dL (n=67) for control animals and 110 
22.2 ± 0.9 μg/dL (n=47) for Pb2+-exposed animals. This exposure level is 111 
environmentally relevant and previous studies using this animal model have shown 112 
deficits in synaptic plasticity23, decreased adult neurogenesis24, and impairments of 113 
spatial learning and contextual fear conditioning23,25,26. 114 
 115 
7,8-DHF reverses the increase in paired-pulse facilitation at Schaffer collateral-116 
CA1 synapses produced by Pb2+ exposure: Neuronal short-term presynaptic plasticity 117 
is often assessed by delivering paired-pulse stimulation, that is, two stimuli to the same 118 
synaptic pathway in close succession27,28. One form of paired-pulse modulation, paired-119 
pulse facilitation (PPF), is typically attributed to an increase of release probability (Pr) 120 
during the second stimulus, arising from prior accumulation of residual Ca2+ near active 121 
zones and/or lingering effects of Ca2+ on a Ca2+ sensor28,29. This residual Ca2+, when 122 
present at terminals that fail to release on the first stimulus, will cause them to release 123 
and increase response amplitude from the second stimulus. Therefore, if initial Pr is 124 
reduced, as by manipulations such as reducing extracellular [Ca2+], the magnitude of 125 
PPF (the ratio of second to first response amplitude) should increase28,29. 126 
 127 
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In Figure 1A the black trace shows that PPF in CA1 pyramidal neurons was elicited by 128 
two Schaffer collateral stimuli applied 30 ms apart. The red trace (Figure 1A) shows the 129 
larger PPF typical of a CA1 pyramidal neuron in a slice from a Pb2+ rat (Pb2+/VEH) while 130 
the blue trace illustrates rescue of PPF in a slice from a Pb2+ rat that also received 7,8-131 
DHF (Pb2+/7,8-DHF). Administration of 7,8-DHF to control animals (CON/7,8-DHF; grey 132 
trace) did not alter PPF. When paired-pulse stimuli were applied at intervals varying from 133 
20-70 msec, PPF was significantly increased compared to slices from untreated control 134 
rats (One-way ANOVA (F(2,29)=9.786, p=0.0006). PPF at a paired-pulse interval of 30 135 
ms was significantly increased in slices from Pb2+-treated rats compared to slices from 136 
control rats (post-hoc Tukey's multiple comparison with Duncan's correction: p=0.008). 137 
Moreover, 7,8-DHF treatment of lead exposed rats significantly reduced PPF at this 30 138 
ms interval, compared to rats exposed to lead alone (post-hoc Tukey's multiple 139 
comparison with Duncan's correction: p=0.029), or to control rats (post-hoc Tukey's 140 
multiple comparison with Duncan's correction: p=0.963), as showed in Figure 1C. One-141 
way ANOVA with repeated measures demonstrated a statistically significant increase in 142 
PPF at all inter-pulse intervals (Figure 1B red circles; p=0.0064) in lead treated rats 143 
compared to controls, while 7,8-DHF administration completely rescued PPF across the 144 
entire paired-pulse profile (Figure 1B, blue circles).  145 
 146 
7,8-DHF reverses the impairment in vesicular release from the rapidly-recycling 147 
vesicle pool produced by Pb2+ exposure: To directly determine whether presynaptic 148 
vesicular release is altered by in vivo Pb2+ exposure, we used two-photon excitation to 149 
visualize release of the styryl dye FM1-43 from the rapidly-recycling pool (RRP) of 150 
presynaptic vesicles after selective loading by hypertonic shock in Schaffer collateral-151 
CA1 terminals in hippocampal slices. Presynaptic vesicles in the RRP were first 152 
stimulated by a brief hypertonic shock to fuse with the membrane and release their 153 
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transmitter, which induces them to take up FM1-43 from the extracellular space, followed 154 
by endocytosis and recycling back into the rapidly-recycling pool for the next evoked 155 
release. We have used this method previously to show that generation of long-term 156 
potentiation (LTP) and long-term depression (LTD) is associated with persistent 157 
increases30 or decreases31 in the rate of stimulus-evoked FM1-43 de-staining at Schaffer 158 
collateral terminals, and that chronic early life Pb2+ exposure persistently reduces 159 
vesicular release from the RRP19. 160 
 161 
Figure 2 illustrates the effect of Pb2+ exposure on vesicular release from Schaffer 162 
collateral presynaptic terminals. Figure 2A shows representative pseudocolor images of 163 
FM1-43 labelled Schaffer collateral terminals before (Baseline) and after 12 minutes of 2 164 
Hz stimulation in control slices from rats that received daily injections of vehicle 165 
(CON/VEH) or 7,8-DHF (CON/7,8-DHF), versus slices from Pb2+ rats with vehicle 166 
(Pb2+/VEH) or Pb2+ rats that received 7,8-DHF (Pb2+/7,8-DHF). The slice from the Pb2+-167 
exposed rat showed markedly slower stimulus-evoked de-staining compared to the 168 
control slice, while rapid de-staining was restored in the slice from the Pb2+ rat that 169 
received 7,8-DHF. Figure 2B summarizes the time courses of all slices, showing the 170 
markedly slower vesicular release evoked by 2 Hz stimulation of Schaffer collateral 171 
terminals in field CA1 of slices from Pb2+ rats (red filled circles) compared to controls 172 
treated with vehicle (black open circles) or controls treated with 7,8-DHF (grey solid 173 
circles), and the rescue of this effect in slices from Pb2+ rats treated with 7,8-DHF (blue 174 
solid circles). Statistics with one way ANOVA (F(3,102)=50.73, p<0.0001) on the initial 175 
time constant of release calculated from a single exponential fit of the first 6 times 176 
points30,31 exhibited a significant slower decay constant in rats exposed to Pb2+ alone 177 
(red bar, p=0.0001), compared to control rats treated with vehicle (open bar), 7,8-DHF 178 
alone (grey bar, p=0.504), or Pb2+-exposed rats also given 7,8-DHF (blue bar, p=0.711). 179 
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 180 
7,8-DHF reverses Pb2+-induced reductions in presynaptic Schaffer collateral 181 
release probability measured by variance-mean analysis: Variance-mean (VM) 182 
analysis using a binomial model of synaptic transmission has been employed to study 183 
neurotransmitter release probability at a variety of synapses32,33. It is typically applied to 184 
steady-state sequences of single evoked EPSCs recorded while varying extracellular 185 
[Ca2+], or delivering long repetitive trains of stimulation of different frequencies, each 186 
resulting in a range of mean response size with variance that is a parabolic function of 187 
Pr34-37. In this method, low extracellular [Ca2+] yields low Pr, release failures and low 188 
EPSC variance, high extracellular [Ca2+] yields high Pr, few failures and, again, low 189 
EPSC variance, and physiological extracellular [Ca2+] yields intermediate Pr and higher 190 
EPSC variance. We have applied this method to directly estimate presynaptic Pr at 191 
Schaffer collateral-CA1 synapses, comparing normal slices to slices from Pb2+-exposed 192 
rats using the identical protocol as in the current study19. 193 
 194 
Figure 3A demonstrates that the VM relationship obtained by varying extracellular [Ca2+] 195 
was parabolic, with maximum variance at the peak of the parabola. In pyramidal 196 
hippocampal neurons from Pb2+ rats (Pb2+/VEH), individual slice data point (Figure 3A, 197 
red circles) and mean amplitudes (Figure 3B, red circles) at different [Ca2+], converted to 198 
Pr, were reduced along the same parabolic fit at all three [Ca2+], consistent with a 199 
reduction in presynaptic release probability compared to CON/VEH/7,8-DHF (black open 200 
circles). It should be noted that the CON/VEH/7,8-DHF is the combined data from 201 
CON/VEH and CON/7,8-DHF animals since there was no significant differences 202 
between these two groups. The groups were combined in order to make panel A and B 203 
graphs easier to understand. The actual data for each group is provided in Table 1. 204 
 205 
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Across all experiments (Table 1), Pr calculated by this method was significantly reduced 206 
in slices from Pb2+/VEH rats at low (1/4 mM, p=0.007), medium (2/2 mM, p=0.005) and 207 
high (4/1 mM, p=0.005) [Ca2+]/[Mg2+] ratios (One-way ANOVA with repeated measures 208 
(F(8,69)=25.14, p=0.001). Figure 4 shows a variance/mean versus mean linear plot, 209 
where the line fit from pyramidal neurons from a CON/VEH (black dotted line) versus a 210 
Pb2+/VEH (red dotted line) rat significantly differed in slope (p=0.015), consistent with a 211 
presynaptic site of reduced Pr. This shift in slope was rescued in a slice from a Pb2+ rat 212 
treated with 7,8-DHF (Figure 4, blue dotted line). Again, the CON/7,8-DHF data was not 213 
different from CON/VEH and it was not included to simplify the graph, but it is provided 214 
in Table 2. These shifts in Pr were not associated with significant changes in number of 215 
release sites (N) or quantal size (Q) across all slices (Table 2). 216 
 217 
7,8-DHF reverses Pb2+-induced reductions in presynaptic calcium influx into 218 
Schaffer collateral terminals: Calcium channels (P/Q and N-type) are the major source 219 
of action potential mediated Ca2+ influx into presynaptic terminals. Previous studies have 220 
shown that Pb2+ inhibits calcium channels in cultured cells, an effect that is reversible by 221 
washing the cellular preparation38. If Pb2+ exposure chronically alters the activity of these 222 
channels, this could indirectly contribute to alterations in Pr. To directly test whether 223 
chronic Pb2+ exposure produces a persistent inhibition of presynaptic Ca2+ influx, and to 224 
determine if 7,8-DHF can reverse such effects, we injected Mg2+ Green-AM, a calcium 225 
indicator dye that is membrane-permeable39, directly into stratum radiatum of field CA1 226 
of hippocampal slices. Mg2+ Green positive fluorescent puncta were visualized in field 227 
CA1 using two-photon excitation. Figure 5 demonstrates the kinetics of Mg2+ Green 228 
fluorescence increases in response to a 100 Hz burst of four Schaffer collateral stimuli. 229 
We have shown previously that these responses persist in the presence of NMDA and 230 
AMPA receptor antagonists, despite the loss of fEPSPs, are blocked by cadmium and 231 
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omega conotoxin, and co-localize with FM4-64, confirming a presynaptic nature for 232 
these calcium transients40. 233 
 234 
Comparison of mean fluorescence increases of representative stimulus-evoked 235 
presynaptic Ca2+ influx transients in Schaffer collateral terminals in slices from vehicle 236 
control (CON/VEH; Figure 5A black trace) or control treated with 7,8-DHF (CON/7,8-237 
DHF; Figure 5A grey trace), versus Pb2+ rats (Pb2+/VEH; Figure 5A red trace) and Pb2+ 238 
rats treated with 7,8-DHF (Pb2+/7,8-DHF; Figure 5A, blue trace), revealed that action 239 
potential-dependent Ca2+ influx was reduced in amplitude by Pb2+ exposure, and that 240 
7,8-DHF was able to reverse this reduction in presynaptic Ca2+ influx. Figure 5B 241 
summarizes these results across all slices, showing that Schaffer collateral presynaptic 242 
terminals in hippocampal slices from Pb2+ rats (red bar) exhibited reduced Ca2+ influx 243 
(One-way ANOVA with repeated measures F(3,28)=5.233, p=0.0054) compared to 244 
vehicle control slices (black bar, p=0.0129), 7,8-DHF treated slices (grey bar, p=0.0192), 245 
or slices from rats exposed to Pb2+ plus 7,8-DHF injections (blue bar, p=0.0269). Taken 246 
together, our data indicate that chronic exposure to Pb2+ during development results in a 247 
persistent reduction in presynaptic Pr that may be due to both reduced Ca2+ influx, and 248 
actions downstream of presynaptic Ca2+ influx at the level of SNARE protein-mediated 249 
exocytosis16-18. Consistent with its effects in rescuing Pr, daily injection of 7,8-DHF was 250 
also able to rescue the effects of Pb2+ exposure in reducing presynaptic Ca2+ influx at 251 
Schaffer collateral terminals in the hippocampus. 252 
 253 
 254 
 255 
 256 
 257 
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DISCUSSION 258 
Our current study identifies a novel therapeutic target with the potential to treat Pb2+-259 
intoxicated children. Daily postnatal administration of the cell permeant TrkB receptor 260 
agonist 7,8-DHF, which readily crosses the blood-brain barrier, completely rescued Pb2+-261 
induced reductions in vesicular release and presynaptic Ca2+ influx, supporting its 262 
potential as a novel treatment for the cognitive effects of early life Pb2+ exposure. 7,8-263 
DHF is a naturally occurring small molecule in the flavonoid family of polyphenolic 264 
compounds found in Godmania aesculifoloia, Tridax procumbens, and primula tree 265 
leaves41,42. It has been shown to be neuroprotective in preclinical studies43,44. However, 266 
further studies are needed to determine whether the rescue of transmitter release by 267 
7,8-DHF is long-lasting or permanent, and whether it rescues behavioral impairments 268 
associated with chronic developmental exposure to Pb2+.  269 
 270 
Previous studies using acute exposure to Pb2+ in cultured cells have shown inhibition of 271 
Ca2+ channels by Pb2+, an effect that is reversed upon washout of Pb2+ from the cells38. 272 
There could be additional mechanisms by which Pb2+ persistently alters vesicular 273 
release, such as changes in levels of SNARE proteins that we have shown 274 
previously16,17. In this study, fluorescent imaging of presynaptic Ca2+ influx showed that 275 
Pb2+ exposure was associated with reductions in voltage-dependent Ca2+ channel-276 
mediated Ca2+ entry that were completely reversed by 7,8-DHF. Previously, we found 277 
that presynaptic Ca2+ fluorescent signals evoked by brief 20 Hz bursts of stimulation 278 
showed only a small, early reduction in amplitude of presynaptic Ca2+ signals in slices 279 
from Pb2+ rats19, leading us to use higher frequency 100 Hz bursts of stimulation in this 280 
study. Our present findings suggest that developmental Pb2+ exposure can persistently 281 
impair presynaptic Ca2+ entry, and have additional downstream effects at the level of 282 
vesicular SNARE protein-mediated docking, recycling, and long-term stability of the 283 
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release complex, consistent with our previous findings in hippocampal neuronal 284 
cultures16, and hippocampal slices from Pb2+ rats19. 285 
 286 
In this study, rats were exposed to Pb2+ chronically during gestation, postnatally and 287 
continuing through to young adulthood. The artificial cerebrospinal fluid used to maintain 288 
slice viability during experiments did not contain Pb2+, indicating that the effects 289 
observed were the result of the in vivo Pb2+ exposure. Our studies have previously 290 
shown16 that BDNF synthesis and release are decreased in cultured hippocampal 291 
neurons exposed to Pb2+, and are associated with reductions in levels of SNARE 292 
proteins and inhibition of vesicular release. These effects of in vitro Pb2+ exposure, were 293 
rescued by exogenous BDNF, consistent with our present findings. Stansfield et al.18, 294 
using the same Pb2+ exposure paradigm in cultured neurons, showed that Pb2+ may 295 
impair the transport of BDNF-containing vesicles, possibly by altering Huntingtin 296 
phosphorylation at a site promoting anterograde BDNF vesicle movement. This effect of 297 
Pb2+ resulted in impaired BDNF release, decreasing TrkB activation, and 298 
phosphorylation of synapsin I. Our current findings further support the hypothesis that 299 
BDNF receptor agonists and treatments such as enriched environments that increase 300 
BDNF levels and release45,46, may be able to rescue the effects of chronic Pb2+ exposure 301 
we observed in more intact hippocampal synaptic networks. Further, previous studies 302 
from our laboratory have shown that environmental enrichment can reverse Pb2+-303 
induced impairments of spatial learning in rats of similar age and Pb2+ treatment47. This 304 
study also showed that Pb2+-exposed rats placed in an enriched environment that 305 
reverses learning deficits, also exhibit increased BDNF gene expression in the 306 
hippocampus47, supporting our current data implicating the BDNF-TrkB system in Pb2+ 307 
neurotoxicity and suggesting the BDNF mimetic 7,8-DHF as a potential therapy for Pb2+-308 
intoxicated children. 309 
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 310 
METHODS 311 
Chemicals: Chemicals for extra- and intracellular solutions were purchased from Sigma-312 
Aldrich (St. Louis, MO). Neurotransmitter receptor antagonists were purchased from 313 
Tocris Cookson (Minneapolis, MN), and FM1-43 from Invitrogen (Grand Island, NY). 314 
 315 
Blood Pb2+ analysis: Blood Pb2+ levels in samples from littermates were measured using 316 
the LeadCare system (Magellan Diagnostics, N. Billerica, MA). 317 
 318 
Animals: Adult female Long-Evans rats (250 g) were purchased from Charles River, Inc. 319 
(Wilmington, MA) and randomly placed on diet containing 0 (control) or 1500 ppm lead 320 
acetate (PbAc) (Dyets, Bethlehem, PA) 10 days prior to breeding with non-exposed 321 
Long-Evans males (300 g). Litters were culled to 10 pups on postnatal day 1 (PN1). 322 
Dams were maintained on their respective diet and at PN21 male pups were weaned 323 
onto the same diet and maintained until PN50. All rats are housed in plastic cages at 22 324 
± 2°C on a 12/12 light:dark cycle. Food and water were allowed ad libitum. Each litter is 325 
a single experimental unit for statistical purposes, so that for each experiment only one 326 
animal per litter was used for one data point. All studies were conducted in accordance 327 
with the United States Public Health Service’s Policy on Human Care and Use of 328 
Laboratory Animals under protocols approved by Institutional Animal Care and Use 329 
Committees from each university. 330 
 331 
Hippocampal slice electrophysiology: Experiments were conducted as described 332 
previously19,30,31. At 50 ± 2 days of age, rats were deeply anesthetized with isoflurane, 333 
decapitated and their brains rapidly removed and submerged in ice-cold artificial 334 
cerebrospinal fluid (ACSF, 2–4 °C), containing (in mM): 124 NaCl, 4 KCl, 2 MgCl2, 2 335 
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CaCl2, 1.25 NaH2PO4, 26 NaHCO3, 10 glucose; at pH 7.4, gassed continuously with 336 
95% O2/5% CO2). Brains were hemisected, the frontal lobes cut off, and individual 337 
hemispheres glued using cyanoacrylate adhesive onto a stage immersed in ice-cold 338 
ACSF gassed continuously with 95% O2/5% CO2 during slicing. We cut 400 µm thick 339 
coronal slices using a vibratome (Leica VT1200S), and transferred them to an interface 340 
holding chamber for incubation at room temperature for a minimum of 1 hr before 341 
transferring to a submerged recording chamber continuously on a Zeiss Axioskop 342 
microscope continuously perfused at 3 ml/min with oxygenated ACSF at 32 ± 0.5 °C. 343 
 344 
Whole cell patch-clamp recordings were performed in CA1 pyramidal neurons using 345 
standard techniques. Patch pipettes (R=3-4 MΩ) were filled with recording solution 346 
containing (in mM): 135 CsMeSO3, 8 NaCl, 10 HEPES, 2 Mg-ATP, 0.3 Na-GTP, 0.5 347 
EGTA, and 1 QX-314 (275 mOsm, pH 7.25 adjusted with Cs(OH)2).  Access resistance 348 
was carefully monitored, and only cells with stable access resistance (<5% change) 349 
were included in analyses. CA1 pyramidal cells were recorded under voltage clamp 350 
using a MultiClamp 700B (Axon Instruments) with Clampex (v9). Recording signals were 351 
filtered through an eight-pole Bessel low-pass filter with a 3 kHz cutoff frequency, 352 
digitized at 10 kHz, and sampled using Clampex (v9). Neurons were clamped at –60 353 
mV, and Schaffer collateral-evoked EPSCs were delivered by a bipolar stimulating 354 
electrode (FHC, USA, 50-100 pA, 100 µs duration). EPSC slopes were calculated by 355 
linear interpolation of the initial downward current from 20% to 80% of the maximum 356 
EPSC amplitude. Paired-pulse facilitation was assessed by applying a pair of Schaffer 357 
collateral stimuli at intervals of 10-125 msec, and the ratio of slopes of the second to the 358 
first response was calculated, so that numbers greater than 1.0 represented facilitation, 359 
less than 1.0 inhibition.  360 
 361 
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 362 
 363 
Two-photon laser scanning microscopy 364 
Vesicular release FM1-43 fluorescence measurements: Fluorescence was visualized 365 
using a customized two-photon laser-scanning Olympus BX61WI microscope with a 366 
60x/0.90W water immersion infrared objective lens and an Olympus multispectral 367 
confocal laser scan unit. The light source was a Mai-Tai™ laser (Solid-State Laser Co., 368 
Mountain View, CA), tuned to 860 nm for exciting Magnesium Green and 820 nm for 369 
exciting FM1-43. Epifluorescence was detected with photomultiplier tubes of the 370 
confocal laser scan head with pinhole maximally opened and emission spectral window 371 
optimized for signal over background. In the transfluorescent pathway, a 565 nm dichroic 372 
mirror was used to separate green and red fluorescence to eliminate transmitted or 373 
reflected excitation light (Chroma Technology, Rockingham, VT). After confirming the 374 
presence of Schaffer collateral-evoked fEPSPs >1 mV in amplitude in CA1 stratum 375 
radiatum, and inducing LTP, 10 µM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) was 376 
bath-applied throughout the rest of the experiment to prevent synaptically-driven action 377 
potentials in CA3 pyramidal neurons from accelerating dye release. Presynaptic boutons 378 
were loaded by bath-applying 5 µM FM1-43 (Molecular Probes) in hypertonic ACSF 379 
supplemented with sucrose to 800 mOsm for 25 sec to selectively load the rapidly-380 
recycling pool (RRP)30,31, then returned to normal ACSF. Stimulus-induced destaining 381 
was measured after 30 min perfusion with dye-free ACSF, by bursts of 10 Hz bipolar 382 
stimuli (150 µs DC pulses) for 2 sec applied once each 30 sec. We fitted a single 383 
exponential to the first 6 fluorescence time course values, and decay time constants 384 
between groups compared by two-tailed Student’s t-test, as we have shown previously 385 
that the early release reflects vesicular release from the RRP prior to recycling and 386 
reuse of vesicles30,31.  387 
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 388 
Presynaptic Ca2+ influx fluorescence measurements: Using established methods for 389 
measuring [Ca2+] transients48, we filled Schaffer collateral presynaptic fibres with 390 
Magnesium Green AM. Briefly, an ejection electrode (tip diameter, 5-10 µm) containing 391 
Magnesium Green AM (1 mM Magnesium Green AM, 10% DMSO, 1% pluronic acid in 392 
ACSF) was lowered into the Schaffer collateral pathway between the stimulating 393 
electrode and the presynaptic terminal field to be observed, air pressure pulses (6-9 psi, 394 
100-200 msec) controlled by a Picospritzer (General Valve Corp. USA) were applied to 395 
the electrode until a small bright spot (≈10 mm in diameter) was observed. Thirty 396 
minutes elapsed to allow dye to sufficiently diffuse into presynaptic boutons prior to 397 
commencing imaging. To verify that magnesium green selectively loaded presynaptic 398 
terminals, FM4-64 was loaded with high [K+]o at the end of the experiment. To measure 399 
Ca2+ dynamics, stimulus-evoked fluorescence signals were collected by scanning at 200 400 
Hz in surface-scanning mode (XYT). Baseline fluorescence (F0) was averaged over four 401 
images, and ∆F/F calculated as (∆F/F)(t)=(F(t)-F0)/F0. 402 
 403 
Estimation of presynaptic release probability by variance-mean (VM) analysis: Variance-404 
mean (VM) analysis according to a binomial model of synaptic transmission is a method 405 
that has been employed to study transmitter release at many synapses32,33,49. It is mainly 406 
applied to steady-state sequences of evoked EPSCs recorded under a variety of 407 
conditions by varying extracellular [Ca2+], or delivering long repetitive trains of stimulation 408 
of different frequencies, each resulting in a range of mean response size34-37.  409 
 410 
We used three ratios of [Ca2+]/[Mg2+] in ACSF (4/1, 2/2, and 1/4 mM) to alter release 411 
probability at Schaffer collateral synapses. Experiments began by establishing stable 412 
whole-cell recording from a CA1 pyramidal neuron, and then perfusing the slice with 4/1 413 
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[Ca2+]/[Mg2+] ACSF. Cells were voltage-clamped at -65 mV, and 100 µs constant-current 414 
stimulus pulses were delivered to Schaffer collateral/commissural fiber axons every 10 415 
sec to evoke an EPSC. Stable recordings for 8-10 min were made in 4/1 [Ca2+]/[Mg2+], 416 
before replacing the perfusate with 1/4 mM [Ca2+]/[Mg2+] ACSF. After EPSCs decreased 417 
in amplitude and restabilized, which usually took 5-8 min, EPSCs were recorded for an 418 
additional 8 min. Slices were then perfused with 2/2 mM [Ca2+]/[Mg2+] ACSF. After EPSC 419 
amplitudes had again stabilized, another 8 min of recordings were made. To induce 420 
LTD, slices were exposed to either 10 µM NMDA or 25 µM DHPG in 2/2 mM 421 
[Ca2+]/[Mg2+] ACSF for three or five min, respectively, durations which reliably induced 422 
LTD lasting hours. After drug exposure, slices were perfused with 2/2 mM [Ca2+]/[Mg2+] 423 
ACSF for >30 min, to verify expression of LTD, and then the same sequence of 424 
[Ca2+]/[Mg2+] ACSF applications was repeated. To ensure that postsynaptic AMPA 425 
receptors were responding to non-saturating glutamate concentration, a requirement for 426 
VM analysis, experiments were performed in a low concentration of the AMPA receptor 427 
antagonist 6,7-dinitroquinoxaline-2,3-dione (DNQX, 100 nM). 428 
 429 
7,8-DHF administration: 430 
7,8-Dihydroxyflavone hydrate (DHF, Sigma-Aldrich, St Louis, MO) was dissolved in 431 
phosphate-buffered saline (PBS) containing 17% dimethylsulfoxide (DMSO). Male rats 432 
received daily intraperitoneal injections of 5 mg/kg 7,8-DHF or 17% DMSO vehicle daily 433 
for 14-15 consecutive days starting when they were 35-42 days of age. Rats were 434 
sacrificed for slice preparation twenty-four hours after the last 7,8-DHF administration. 435 
 436 
Statistics: Power analysis showed a group size of 6 animals per treatment group with 437 
significance level pre-set to p<0.05 could detect between group differences of 10% for 438 
vesicular transmitter release time constants and release probability at a power of 85% 439 
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with typical parameter standard deviations. Data sets did not deviate significantly from 440 
normal distribution (D’Agostino-Pearson omnibus normality test), and did not exhibit 441 
significant differences in parameter variances (F-test). Slices and treatments were 442 
randomized, with treated and control slices examined in parallel on the same or 443 
sequential days. While all analyses were automated, the investigator was not blinded to 444 
treatment group. Student’s t-test was used to determine differences between the control 445 
and Pb2+ treated groups for each particular measure. In analyses requiring comparisons 446 
between multiple groups, a one-way ANOVA with Sidak’s Multiple Comparisons analysis 447 
was used with post-hoc Tukey’s test for individual group comparisons. Significance level 448 
was preset to p< 0.05. 449 
 450 
Data Availability: Following calculation of EPSP slopes, paired-pulse ratios or optical 451 
time courses of vesicular release and presynaptic calcium influx, all data will be made 452 
available upon request. Image analysis was performed with ImageJ (NIH), statistical 453 
analyses with GraphPad Prism v6 (La Jolla, CA), and custom-built, proprietary software 454 
was used to control the multi-photon laser scanner for FM1-43 imaging experiments, 455 
which is copyrighted by the designer and cannot be made available. 456 
 457 
 458 
 459 
 460 
 461 
 462 
 463 
 464 
 465 
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 637 
FIGURES 638 
Figure 1: 7,8-DHF reverses the 639 
increase in paired-pulse facilitation 640 
(PPF) produced by Pb2+ exposure at 641 
Schaffer collateral-CA1 synapses in rat 642 
hippocampus. (A) Representative 643 
excitatory postsynaptic currents 644 
(EPSC) in field CA1 in response to 645 
Schaffer collateral paired-pulse stimuli 646 
at a 30 ms interstimulus interval (ISI) in 647 
slices from Control (CON/VEH; black 648 
trace), Pb2+-treated (Pb2+/VEH; red 649 
trace) and Pb2+ + 7,8-DHF-treated rats 650 
(Pb2+/7,8-DHF; blue trace), illustrating 651 
the ability of 7,8-DHF to reverse Pb2+-652 
induced increases in PPF. (B) Mean ± 653 
SEM EPSC PPF P2/P1 ratio as a 654 
function of ISI, where PPF was 655 
significantly enhanced for ISI 20-70 ms 656 
in slices from Pb2+-treated (filled red 657 
circles, N=9 slices) versus controls 658 
(open black circles, N=13 slices), and 659 
this effect was rescued by treatment of 660 
Pb2+ rats with 7,8-DHF (filled blue circles, N=10 slices) (p<0.05). (C) Mean ± SEM ratio 661 
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of P2/P1 (30 ms ISI) at Schaffer collateral-CA1 synapses in slices from control (open 662 
bar), Pb2+-treated (red bar), and Pb2+ plus 7,8-DHF-treated rats (blue bar), showing that 663 
increased PPF in Pb2+-treated rats (p<0.05) was rescued by 7,8-DHF co-administration. 664 
 665 
 666 
Figure 2: Two-photon laser scanning microscopic (TPLSM) images of FM1-43 vesicular 667 
release from Schaffer collateral terminals in field CA1 of hippocampal slices show that 668 
Pb2+-induced persistent reduction in release probability is rescued by 7,8-DHF. (A) 669 
Representative TPLSM pseudocolor images of FM1-43 loaded presynaptic terminals in 670 
stratum radiatum of field CA1 in hippocampal slices from a Pb2+ rat (Pb2+/VEH), versus a 671 
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rat treated with Pb2+ plus 7,8-DHF (Pb2+/7,8-DHF), and one treated with DHF alone 672 
(CON/7,8-DHF), or control vehicle (CON/VEH) imaged prior to (Baseline) and after 12 673 
min 2 Hz Schaffer collateral stimulation (Calibration Bar: 5 µm). (B) Time course (Mean 674 
± SEM) of stimulus-evoked FM1-43 de-staining from puncta in field CA1 of hippocampal 675 
slices in response to 2 Hz Schaffer collateral stimulation in slices from control rats (open 676 
circles, N=8 slices, 35 puncta) versus Pb2+-treated (red circles, N=6 slices, 30 puncta), 677 
and Pb2+ plus 7,8-DHF-treated rats (grey diamonds, N=8 slices, 36 puncta). (C) Mean ± 678 
SEM of initial fluorescence decay time constant in slices from Pb2+-treated rats 679 
(Pb2+/VEH), versus rats treated with Pb2+ plus 7,8-DHF (Pb2+/7,8-DHF), and control rats 680 
treated with 7,8-DHF alone (CON/7,8-DHF) or vehicle (CON/VEH). All slices from Pb2+ 681 
rats showed significantly slower de-staining of Schaffer collateral terminals (p<0.05) 682 
compared to control slices, and this reduction was completely rescued by 7,8-DHF. 683 
 684 
 685 
Figure 3: Chronic Pb2+ exposure is associated with reduced presynaptic vesicular 686 
release probability at Schaffer collateral-CA1 terminals assessed by variance/mean 687 
analysis. (A) Individual variance/mean data points, corrected to estimate Pr, at each 688 
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[Ca2+]o for each CON/VEH/7,8-DHF (open black circles), each slice from a Pb2+ rat 689 
(Pb2+/VEH; open red circles), and each slice from a Pb2+ rat administered 7,8-DHF 690 
(Pb2+/7,8-DHF; blue circles). Data from all groups of slices were well fit by a single 691 
parabola forced to pass through 0,0 with Pb2+ synapses shifted to the left, consistent 692 
with a presynaptic reduction in Pr from chronic Pb2+ exposure. This shift was rescued by 693 
7,8-DHF. (B) Mean ± SEM of variance/mean points in slices from CON/VEH/7,8-DHF 694 
(black circles; N=11), Pb2+/VEH (red circles; N=8), and Pb2+/7,8-DHF (blue circles; N=8), 695 
normalized to the maximal peak amplitude recorded at 4 mM [Ca2+]o. 696 
 697 
 698 
Figure 4: Plot of variance/mean ratio versus mean EPSC amplitude (pA) from a single 699 
representative slice, which converts the parabolic relationship between mean and 700 
variance to a linear one. The number of release sites (N) was derived by estimating the 701 
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slope of the linear fit, while the y-intercept denotes quantal size (Q) of the EPSC. The 702 
reduction in slope indicates that chronic Pb2+ exposure (Pb2+/VEH; red dotted line) was 703 
associated with a reduction in presynaptic Pr compared to a control slice (CON/VEH; 704 
dotted black line), that was partially reversed in a slice from a Pb2+-exposed rat 705 
administered 7,8-DHF (Pb2+/7,8-DHF; dotted blue line). 706 
 707 
 708 
Figure 5: 7,8-DHF rescues Pb2+-induced reductions in presynaptic Ca2+ influx into 709 
Schaffer collateral terminals. (A) Representative fluorescent transients evoked by 710 
Schaffer collateral stimulation in single presynaptic terminals of a Control slice 711 
(CON/VEH; black trace), a control slice with 7,8-DHF (CON/7,8-DHF; grey trace), a slice 712 
from a Pb2+ rat (Pb2+/VEH; red trace), and a slice from a Pb2+ rat administered 7,8-DHF 713 
(Pb2+/7,8-DHF; blue trace). (B) Mean ± SEM presynaptic stimulus-evoked Mg2+-Green 714 
fluorescence increases in presynaptic terminals in response to a burst of Schaffer 715 
collateral stimuli (4x20Hz) in slices from control (CON/VEH, N=8 slices, 16 terminals) 716 
versus Pb2+-exposed (Pb2+/VEH, N=8 slices, 14 terminals) rats, and slices from Pb2+-717 
exposed rats co-administered 7,8-DHF (Pb2+/7,8-DHF, N=8 slices, 16 terminals). Ca2+ 718 
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influx transients were significantly smaller in terminals of Pb2+-exposed rat slices 719 
compared to either controls or 7,8-DHF rescued slices (p<0.05). 720 
 721 
 722 
Table 1: Presynaptic release probability estimated from variance/mean analysis as a 723 
function of ratio of [Ca2+]/[Mg2+] 724 
Ca2+/Mg2+ 
CON/VEH CON/7,8-DHF Pb2+/VEH Pb2+/7,8-DHF 
Mean ± SD N Mean ± SD N Mean ± SD N Mean ± SD N
1/4 0.050 ± 0.009 8 0.049 ± 0.002 3 0.037 ± 0.003 * 8 0.058 ± 0.022 8
2/1 0.451 ± 0.053 8 0.445 ± 0.052 3 0.288 ± 0.075 * 8 0.480 ± 0.058 8
4/1 0.726 ± 0.073 8 0.753 ± 0.098 3 0.603 ± 0.067 * 8 0.764 ± 0.070 8
 725 
* = p<0.05, Student’s t-test with Bonferroni correction; N= number of slices 726 
 727 
 728 
Table 2: Numbers of release sites and quantal amplitude estimated by variance/mean 729 
analysis at Schaffer collateral synapses in field CA1 730 
 
CON/VEH CON/7,8-DHF Pb2+/VEH Pb2+/7,8-DHF 
Mean ± SD N Mean ± SD N Mean ± SD N Mean ± SD N
N. Release 144 ± 57 8 108 ± 60 8 130 ± 53 8 126 ± 58 8 
Quantal Amp 2.63 ± 0.48 8 2.56 ± 0.93 8 2.53 ± 0.58 8 2.43 ± 0.79 8 
 731 
N= number of slices 732 
 733 
